News from amplyx pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 24, 2019, 08:00 ET Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...


Sep 16, 2019, 08:00 ET Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...


Sep 16, 2019, 08:00 ET Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...


Sep 09, 2019, 08:00 ET FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...


Apr 12, 2019, 08:00 ET Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that three posters from the...


Feb 11, 2019, 08:00 ET FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug...


Nov 13, 2018, 08:00 ET Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been ...


Jun 07, 2018, 08:00 ET Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its...


Jun 05, 2018, 08:00 ET Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the company's president...


Apr 30, 2018, 02:15 ET Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that preclinical data...


Mar 19, 2018, 08:40 ET Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, including deadly fungal pathogens, today...


Jan 08, 2018, 08:00 ET Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal...


Oct 09, 2017, 08:00 ET Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017

Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented...


Sep 21, 2017, 08:00 ET Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that...


Aug 02, 2017, 08:00 ET Amplyx Pharmaceuticals Raises $67 Million in Series C Financing

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67...


Jan 05, 2017, 08:00 ET Amplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced the appointments of...


Nov 16, 2016, 08:06 ET FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, announced today that the U.S. Food and...


Sep 12, 2016, 08:00 ET Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

Amplyx Pharmaceuticals today announced the initiation of dosing in a Phase 1 clinical trial of APX001 in healthy volunteers. The randomized,...


Jun 14, 2016, 08:00 ET Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections

Amplyx Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP)...


May 24, 2016, 08:00 ET Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors

Amplyx Pharmaceuticals today announced the appointment of Paul C. Grint, M.D., to its Board of Directors. Dr. Grint, president and CEO, Regulus...


Feb 09, 2016, 08:00 ET Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million

Amplyx Pharmaceuticals today announced that the company has expanded its management team with the appointments of Michael Hodges, M.D., as chief...


Nov 11, 2015, 08:00 ET Amplyx Pharmaceuticals Secures $40.5 Million in Series B Financing

Amplyx Pharmaceuticals today announced the company has closed on a $40.5 million Series B financing. The round was led by RiverVest Venture Partners, ...